Seeking Alpha

Sarepta Therapeutics (SRPT +1.8%) gains this morning after Deutsche Bank SRPT) with a Buy rating...

Sarepta Therapeutics (SRPT +1.8%) gains this morning after Deutsche Bank starts coverage with a Buy. Deutsche says SRPT's Eteplirsen, a treatment for Duchenne Muscular Dystrophy, is likely will be given the green light by mid-2015. The drug has a better safety profile versus its competitor Drisapersen, which will allow it to take a majority share. Fair-value of Eteplirsen in the U.S. alone is around $45 per share, and has tremendous upside potential if the street assigns value to European markets.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|